Counteracting poisoning with chemical warfare nerve agents

The first known AChE inhibitor, tetraetylpyrophosphate (TEPP), was discovered by a French chemist Philippe de Clermont in 1854 (1). Yet, neither the toxicity nor the mode of action of TEPP was known at the time. It was not until 1932, when Willy Lange synthesised some compounds containing the P-F bound, that the toxic effects of exposure to the vapours of OP compounds were observed (9). Although Lange seemed to be aware of the potential pesticidal activity of OP compounds, he never pursued it. A German chemist Gerhard Schrader later developed a new simple method to synthesise TEPP, which then became the first commercial OP insecticide. In 1936, while working for a chemical corporation IG Farben in search for new potential insecticides, Schrader synthesised (R/S)-ethyl N,N-dimethylphosphoramido cyanidate (tabun), for which he found to be too toxic for application in agriculture (10). IG Farben reported tabun discovery to the German Ministry of War, which lead to a chemical weapons programme intended to develop highly toxic and volatile NAs for military purposes. This is how sarin (GB), soman (GD), and cyclosarin (GF) were developed besides tabun (GA) between 1936 and 1949 (11). Fortunately, this so-called “G” (Germany) series of NAs was never used in WWII.

NAs were also synthesised during the Cold War by both the Western and Eastern bloc. The United Kingdom synthesised VX, the representative of “V” agents, in homage to the victory of the Allied forces in WWII, and the United States developed it further for military purposes (12). The Soviet Union generated compounds similar to the V agents, such as VR, also known as Russian VX, and a new generation of compounds known as “intermediate volatility agents” (IVA). One variant of IVA, known as GV, was also developed in the United States (13, 14).

The end of the Cold War saw the development of yet another class of NAs in the Soviet Union, called Novichok agents. In the early 1990s, a Soviet defector Vil Mirzayanov exposed a chemical weapons programme known as Foliant, and revealed the chemical structures of several Novichok series compounds: A-230, A232, A-234, A240 (Novichok-5), and A-262 (Novichok-7) (15, 16). Novichok agents were developed as binary agents and are more potent than VX, the most hazardous among NAs (15). The main advantage of binary agents is the reduced risk of accidental dispersion and poisoning, since chemical precursors are separated and less toxic than the final product (14, 17). The structures of the above mentioned NAs are presented in Figure 1.

Figure 1

Although NAs, tabun in particular, were produced and stockpiled by the German army in WWII, tabun and sarin were first used by the Iraq military against Iranian troops and civilians in the Iran-Iraq War of 1983–1988 (11, 18). Considering their relatively undemanding synthesis, NAs were also used in terrorist attacks, such as the one in Matsumoto, Japan in 1994, and six months later in the Tokyo subway, when thousands of people were poisoned and 19 died (11). In 1995, many countries, including the USA, signed the Chemical Weapons Convention, agreeing to destroy their stockpiled chemical warfare agents, including NAs, by 2012. The Convention entered into force in 1997, and 193 states have signed it since then (19).

Despite vigorous and worldwide control of chemical warfare agent threat by the Organization for Prohibition of Chemical Weapons (OPCW), between 2013 and 2017, sarin was used in a series of chemical attacks in the Syrian civil war in Damascus and the surrounding East Ghouta region, Aleppo and the nearby Idlib region, and possibly the Hama region (5, 17, 20). VX was used for the assassination of Kim Jong Nam in Malaysia in 2017, and Novichoks in an attempted assassination of the former Russian spy Sergey Skripak and his daughter in Salisbury UK, 2018 (6, 16). More recently (August 2020), Novichoks were used on a Russian politician A. Navalny, as confirmed by several Europian research laboratories and OPCW (21, 22). Apparently, the threat posed by NAs is still very real.

The NAs of the G-series are volatile liquids that evaporate spontaneously at room temperature, unlike VX, which is oily and evaporates very slowly (8, 11, 12). VX is therefore more persistent and will contaminate the environment longer than the G agents. Moreover, VX is lipophilic and will more easily penetrate the skin than the hydrophilic G agents, which are mostly inhaled and penetrate the lungs (8, 23).

NAs are mainly odourless and colourless but can appear darker if they contain impurities. Their toxicity is expressed by the median lethal dose (LD₅₀) or median lethal concentration and time (LCt₅₀). The first is used for the percutaneous route of exposure and the second for exposure through inhalation. The most toxic among the G agents are cyclosarin (LD₅₀ 30 mg/70 kg man) and soman (LD₅₀ 350 mg/70 kg man; LCt₅₀ 25–70 mg/min/m³) (8). However, of all NAs the most toxic is VX, regardless of exposure route (LD₅₀ 10 mg/70 kg man; LCt₅₀ 5–50 mg/min/m³) (8).

All NAs are chiral compounds. Tabun, sarin, cyclosarin, and VX have one chiral centre at phosphorus atom and therefore two isomers [P(+) and P(−)], while soman has an additional stereocentre at a carbon atom of the pinacolyl group, so it has two diastereoisomers, that is, four isomers [C(+)P(+); C(+)P(−) and C(−)P(−); C(−)P(+)] (24, 25).

When the scientists started to look into NA poisoning therapy in the 1930s, symptoms of the exposed victims pointed to atropine as potential remedy. Being a competitive muscarinic receptor antagonist, atropine blocks the effects of ACh on muscarinic receptors but has no effect on nicotinic receptors. Although it does not cross the blood-brain barrier (BBB) readily, it has beneficial effects in the CNS and PNS, against central apnoea, oversecretion, and even convulsions and cardiac toxicity (54, 55). To this day, atropine has remained the first drug of choice against symptoms of NA poisoning, because muscarinic effects it counters are the most life-threatening. In the meantime, alternative, more lipophilic anticholinergic drugs such as benactyzine have been investigated to improve therapy (56).

Since atropine is ineffective against nicotinic effects and does not restore AChE activity, further research focused on finding compounds that could complement atropine, such as nucleophilic agents like hydroxylamine, hydroxamic acid, and oximes, which can restore AChE activity (57). The intent was to synthesise a compound whose nucleophilic potential would enable displacement of the phosphorus moiety conjugated at the catalytic serine of AChE and reactivate the enzyme. In the early 1950s, Irwin B. Wilson and Sara Ginsburg set out to design such a compound. The idea was to use neurotransmitter ACh (because of permanent positive charge on the quaternary nitrogen group) as a template, and their efforts resulted in the synthesis of pyridine-2-aldoxime methiodide, known as pralidoxime or 2-PAM (58). Although synthesised without the knowledge of the AChE active site structure, 2-PAM was the first effective oxime reactivator of phosphylated AChE and remained in clinical use to this day.

The efficacy of 2-PAM varied with NA conjugated to AChE, and scientists directed their efforts toward designing more effective oximes that would cover a broader spectrum of OPs. Soon after 2-PAM, between 1958 and 1960, they synthesised trimedoxime bromide (TMB-4), methoxime (MMB-4), and obidoxime (23, 42).

In the late 1980s, Hagedorn and co-workers synthesised hundreds of oximes of the so-called H-series, among which HI-6 and Hlö-7 stood out (59, 60, 61). 2-PAM, obidoxime, HI-6, and TMB-4 became known as the standard oximes (Figure 3) and have been the only oximes approved for clinical and/or military use so far. Even so, their efficacy is not universal (61, 62, 63). 2-PAM, obidoxime, and HI-6 showed clinically relevant AChE reactivation in cases of sarin poisoning, obidoxime and HI-6 in cases of VX poisoning, and HI-6 in cases of cyclosarin poisoning (64). But none of the standard oximes is efficient against tabun poisoning at clinically relevant parameters (reactivation half-time of approximately 5 min and oxime concentration of <50 μmol/L) (64, 65, 66). The same is the case with soman poisoning due to the fast ageing of the soman-AChE conjugate (24).

Besides not being equally effective for all NAs, standard pyridinium oximes are hydrophilic and cannot pass the BBB due to the charged nitrogen atom. Therefore, only 1–10 % of the oximes’ plasma concentration is present in the brain, and their action is mostly limited to the PNS (67). Moreover, oximes cannot reactivate aged AChE and can also be toxic in doses needed for reactivation of non-aged AChE. This is why many still search for oxime reactivators that could overcome these limitations.

Over the last 70 years, there were many attempts to design and synthesise better AChE reactivators resulted in thousands of candidate compounds. Although some showed more potency in reactivating inhibited AChE than the standard oximes, a universal reactivator is unlikely to be found. Here is why. The accommodation and orientation of an oxime is a key property for successful reactivation (68, 69, 70, 71). Kinetically, the reactivation efficiency of an oxime is primarily attributed to the nucleophilic displacement rate of NA and to the affinity of the phosphylated ChE for the oxime (47, 48, 61, 68, 72, 73, 74, 75). To improve oxime kinetics, scientists have designed and synthesised double- or triple-binding mode reactivators. These compounds interact with multiple subsites of the active centre, including the peripheral anionic subsite of AChE, with the aim to increase enzyme’s affinity for the oxime (74, 76, 77, 78, 79).

The search for potentially more effective reactivators also involved a variety of structural modifications in the number or type of the ring, number and position of oxime moiety, structure and position of connecting linkers, and structure and position of side-chain ligands (74, 80, 81, 82, 83, 84). Some of the research investigated Alzheimer’s drugs like tacrine or donepezil as precursors of new reactivators (85, 86, 87). In addition, a number of studies highlighted piperidine derivatives, tetrahydroacridine and tryptoline moiety-containing compounds, and oximes containing tetrahydroisoquinoline and phenyltetrahydroisoquinoline groups as potent reactivators (79, 86, 88, 89, 90, 91, 92, 93). Several research groups focused on designing centrally acting oximes, compounds with no permanent positive charge but amenable to protonation, which would be able to cross the BBB. Upon establishing the pH-dependent equilibrium in the CNS, the protonated form would reactivate synaptic AChE (76, 91–101). In that respect, recent studies identified the RS 194B oxime as capable of rapidly reversing symptoms caused by a lethal dose of inhaled sarin vapour and paraoxon aerosol in macaques (102, 103).

A number of strategies have also been investigated for better delivery of charged reactivators to the brain like targeting nano-particles (104, 105), using pro-drugs (106), enhancing the compound’s lipophilicity by adding fluoride or chloride to the oxime structure (98, 107, 108), administering efflux transporter P-glycoprotein inhibitors (like tariquidar) (109), or adding a sugar moiety (110, 111).

The tabun-AChE conjugate is especially hard to reactivate (52, 62, 112, 113, 114, 115, 116, 117). One reason is the amino group of tabun, which sterically obscures oxime group access to the phosphorus moiety of tabun bound to the catalytic serine (52). Another is that resonance structures of tabun can be formed due to the free electron pair of the amino group of nitrogen, so the nucleophilicity of the oxime group is probably not high enough to reactivate such conjugate structures (112). Among the standard oximes, TMB-4 showed some potential in reactivating the tabun-AChE conjugate, but the dose required for in vivo application is too toxic (62, 116, 117). So far, studies have shown that only pyridinium oximes with the para-positioned oxime group like K203, K048, K074, and K075 have sufficient potency, superior to TMB-4, to restore AChE activity after tabun inhibition (69, 116, 118). A more recent study with triazole containing oxime library pointed out several oximes that were better reactivators of the tabun-AChE conjugate than obidoxime and 2-PAM (74). As the ambition of finding a unique reactivator is unrealistic, a solution may be in the combination of multiple oximes with complementary reactivity which would cover poisoning with a broad spectrum of NAs (119).

Non-oxime treatment alternatives have also been studied such as non-competitive antagonists and allosteric modulators selectively targeting nicotinic receptors (nAChR). Bispyridinium compound MB327 [ 1,1’-(propane-1,3-diyl)bis(4-tert-butylpyridinium) diiodide] (Figure 4) was found to block the open ion channel of the human muscle-type nAChR (120). Its non-competitive antagonism, as well as in vitro reversal of the neuromuscular blocking action of tabun, soman, and sarin in guinea pigs showed that, unlike oximes, it can protect against several NAs when used in combination with other drugs (121, 122). Recently, a reactivation potential was also discovered with 4-amino-2-[(diethylamino)methyl]phenol (ADOC) (Figure 4) (123). Several structural derivatives of ADOC were synthesised by De Koning’s group, and one of them (named “3l”) proved to be the most potent non-oxime reactivator so far reported (124, 125).

Figure 4

Despite many attempts and an outstanding number of synthesised oxime libraries, however, only a small number of compounds gets to be tested in vivo due to adverse pharmacokinetic and pharmacodynamics properties and/or low reactivation efficacy, especially against tabun or soman.

Another feature of NA poisoning is electrographic seizures, followed by motor convulsions (126). These can quickly progress to status epilepticus (SE) or more severe conditions, all contributing to mortality or neuronal damage in survivors. It is believed that the overstimulation of cholinergic pathways and hypoxia are the main causes of seizure onset (127). Seizures activate neuronal inflammation and induce signalling in astrocytes, which leads to higher expression of the glial fibrillary acidic protein (GFAP) (128). High levels of GFAP, in turn, cause astrogliosis and glial scarring (129). Seizures also activate microglia, which results in the release of both pro-inflammatory (IL-1β, IL-1α, IL-6, IFN-γ) and anti-inflammatory (IL-10, IL-4, TGF-β, arginase) cytokines and reactive oxygen species (ROS) causing oxidative stress (128, 130–132). Therefore, OP-induced seizures require effective treatment to minimise brain damage such as treatment with benzodiazepine anticonvulsants diazepam, lorazepam, and midazolam (133, 134). Other drugs are also being studied to that effect, including agonists of the inhibitory neurotransmitter system or antagonists of the excitatory neurotransmitter system (127) and compounds with neuroprotective properties like anti-glutamatergic drugs, including NMDA antagonists ketamine and gacyclidine or AMPA/GluK1 receptor antagonist tezampanel (135, 136).

Pseudo-irreversible inhibitors like carbamates form a short-living covalent complex with the catalytic serin of AChE. Unlike dephosphylation, decarbamylation is relatively fast and AChE is soon spontaneously reactivated (40, 145, 146). One such natural carbamate, physostigmine (from the plant Physostigma venenosum), has been used in medicine to treat Myastheniae gravis for a while now, and so has the synthetic carbamate neostigmine. These compounds are effective against poisoning with several OPs, but only another carbamate, pyridostigmine, has also been proved effective against soman (141, 142, 147, 148). Pyridostigmine was introduced in military practice for pretreatment of NA poisoning in the 1980s (11, 141, 147), but application at effective doses has shown undesirable side effects (mostly gastrointestinal) and was associated with the Gulf War illness (11, 141, 147, 149). This problem was partly addressed by combining pyridostigmine with anticholinergics trihexyfinidil and benactyzine. The product is called PANPAL and is approved for use in the Czech army (148). Pretreatment with PANPAL and standard post-exposure treatment has been proven effective against the G-series and VX (142, 148). However, pyridostigmine does not cross the BBB, so its prophylactic activity is limited to the PNS (142, 147). Carbamates that penetrate the BBB, like pyridostigmine-aprophen prodrugs (pyridophens) or physostigmine-scopolamine combinations, unfortunately, exhibited unwanted neurobehavioral effects (150, 151).

Research into reversible inhibitors that form noncovalent interactions with AChE (145) has yielded some promising options such as donepezil, huperzine A, and galantamine, which are usually used to treat neurodegenerative disorders like Alzheimer’s disease (152, 153). The most interesting is a plant alkaloid galantamine (found in amaryllis, daffodil, and snowdrop) (152, 153). It crosses the blood-brain barrier, exhibits the neuroprotective properties (nicotinic allosteric ligand), and is not toxic at therapeutic doses (153, 154). Moreover, the half-life of galantamine in circulation is quite long, up to 7 h, and can be administered orally (152, 154).

Oximes are also investigated as reversible AChE inhibitors (23, 142, 155), and a transdermal patch containing HI-6 (TRANSANT) has been approved for use in the Czech and Slovakian military (11, 156). Generally, short circulation half-life, toxicity, and the inability of oximes to cross the BBB are shortcomings that need to be addressed when considering oximes as pretreatment.

Since the late 1980s, research has been looking into enzymes of human or other origin which neutralise NAs in the bloodstream, before they reach target organs or get stored in the adipose tissue. There are such endogenous NA scavengers produced by the organism [e.g. human BChE, paraoxonase (PON1), albumin, animal carboxylesterase] (157–159), but they can only protect against low doses of NAs and either react too slowly with them or prefer the less toxic NA isomer. This is why research has been focused on exogenous bioscavengers that act rapidly against a broad spectrum of NAs, have prolonged circulation life (ideally more than 10 days), have no immunogenic or toxic properties, and are available in sufficient amounts to achieve effective concentrations at a reasonable cost (143, 160, 161). Some of these issues can be addressed by PEGylation or by encapsulating recombinant human or non-human enzymes in nanoparticles (119, 162, 163).

Bioscavengers can be divided in three categories: stoichiometric, oxime-assisted catalytic (also sometimes referred to as pseudo-catalytic), and catalytic (Figure 5).

Figure 5

Stoichiometric bioscavengers react with an NA in a 1:1 ratio, i.e. one molecule of the enzyme is phosphylated by one molecule of NA. This way NA concentration in the bloodstream decreases, but the enzyme remains permanently inhibited. Stoichiometric bioscavengers are considered effective if NA is removed from the bloodstream within one circulation period, which is about 7 min in humans (143).

Human BChE is the most studied stoichiometric bioscavenger (159), as it rapidly reacts with NAs and other OPs. However, its concentration in human plasma is about 50 nmol/L, which is not enough to counteract NA poisoning. In a 70-kg human this concentration should reach ~2400 nmol/L (corresponding to a dose of 200 mg) to protect native AChE against 2-fold soman LD₅₀ (164), and higher concentrations have been shown to protect against as high as 5.5-fold soman and even 8-fold VX LD₅₀ in animal studies (165). These prophylactic concentrations can only be achieved with exogenous BChE.

The most convenient source of human BChE is outdated plasma (166). BChE from this source is a tetrameric protein with a circulatory half-life of about 12 to 15 days and it does not have any toxic or immunogenic effects on people (160, 167).

Considering that the isolation and purification of human BChE from plasma are quite expensive, and the availability of plasma depends on donors, alternative production of recombinant human BChE (168) has been investigated in expression systems such as Chinese hamster ovary cells (169, 170), wine fly cells (171), silkworm larvae (172), tobacco (173), maize (174), rice (175), transgenic goats (176), yeast (177), bacteria (178), and, lately, adenovirus-mediated human BChE delivery (179). The major challenges with these alternatives are that high BChE expression is not easy to achieve and the enzyme has to be purified from toxic contaminants. In this respect, the development of a new affinity method on huprine gel was a ground-breaking achievement, as it reduced the cost and time of purification (171, 180). Another achievement was tetramerisation of monomeric recombinant BChE by adding polyproline peptides (181) or polyethylene glycol polymers (182) or by co-expression of the proline-rich end terminal attachment domain (PRAD) to prolong its circulation life (183). Biological half-life in the bloodstream can also be prolonged by encapsulation, polysialylation, PEGylation, and fusion of recombinant human BChE with albumin (170, 176, 183, 184, 185).

Human recombinant AChE has also been investigated as a potential stoichiometric bioscavenger. Bloodstream-stable nanoparticles containing AChE or plant-derived human AChE have been shown effective in scavenging OP molecules (186, 187). In addition, PEGylated AChE has demonstrated greater scavenging efficiency and higher stereoselectivity for the toxic isomers of soman, tabun, and VX than BChE (188, 189).

Oxime-assisted catalytic bioscavengers are enzyme scavengers combined with an efficient reactivator, which allows them to degrade NAs by continuous cycles of inhibition and reactivation. In these two-component systems, the most important is the rate of dephosphylation, as it has to quicker than aging (116, 190). The most logical approach is to combine human plasma BChE with an oxime to enhance NA degradation. However, combining BChE with standard pyridinium oximes proved to be ineffective, as these oximes are mainly AChE reactivators (191). Research has therefore looked into several promising newly synthesised oximes that reactivate phosphylated BChE (70, 191, 192, 193, 194, 195, 196, 197), and some progress has been achieved with new classes of BChE reactivators like quaternary benzaldoximes (192) imidazole aldoximes (193, 195), cinchona derivatives oximes (196), and hydroxypyridine aldoximes (87, 90). Furthermore, members of the oxime libraries that can cross the BBB were found to effectively reactivate sarin-, cyclosarin-, VX-, and paraoxon-inhibited BChE and AChE (91, 108, 193).

Several studies reported that site-directed mutagenesis of the AChE active site resulted in enzyme variants with increased phosphylation and/or reactivation rate, reduced aging rate, and a combination of these features (68, 161, 190, 198, 199). Combined with an oxime, such enzyme exhibits different in vitro kinetics, which further implies which oxime-enzyme pair could be converted into in vivo scavengers of different OPs (115, 200, 201, 202, 203). Certain AChE mutants have been shown to slow down the aging of their conjugates with soman (188, 190, 204). The most effective among them is the AChE mutant F338A, in which the phenylalanine of the choline binding site at position 338 is mutated to alanine (204, 205). The F338A mutation can readily be combined with the mutation of tyrosine to alanine at position 337 (Y337A) to enlarge the enzyme’s active site gorge dimensions, which should enable the positioning of the oxime in the vicinity of the phosphylated catalytic serine to ensure reactivation (68, 161, 190). The idea of the Y337A/F338A mutant is therefore to slow down aging and speed up the reactivation rate, which was demonstrated in vitro and ex vivo, when soman was quickly degraded in cycles of Y337A/F338A inhibition and reactivation by HI-6 (71, 190). Effective oxime-assisted catalytic soman and VX bioscavenging has also been reported in vivo with sub-stoichiometric amounts of the Y337A/F338A AChE mutant and an oxime reactivator (71, 206).

Other recent ex vivo studies showed some progress with a combination of Y337A and novel pyridinium aldoxime (analogous to 2-PAM) in tabun degradation in whole human blood (78, 161).

Finding an oxime that would effectively reactivate native ChEs in whole blood would be an improvement over stoichiometric or oxime-assisted catalytic scavenging in terms of cost, immunity, or circulation time challenges. Recent studies reported such potential with 3-hydroxy-2-pyridine aldoxime and chlorinated double-charged mono-oxime, which were successful in ex vivo degradation of VX, sarin, cyclosarin, and paraoxon (91, 108).

Catalytic bioscavengers are enzymes that can hydrolyse NAs into non-toxic products. The advantage of catalytic over stoichiometric bioscavengers is that they need lower doses to provide superior protection of native AChE from phosphylation, because one enzyme degrades multiple NAs molecules (207, 208). Several natural occurring human enzymes whose substrates are OPs are being investigated as potential catalytic bioscavengers, such as PON1 from plasma, erythrocyte and liver prolidase, carboxylesterase, platelet activating factor acetylhydrolase, liver senescence marker, and cytosolic aminopeptidases (142, 144, 209, 210, 211, 212).

The greatest interes is for PON1 which hydrolyses several OP compounds at a high rate, it is enantioselective, prefers the more toxic S(–) enantiomer of tabun, but, unfortunately, shows greater enantioselectivity to the less toxic isomers of soman (213, 214). Increasing PON1 catalytic activity up to 100 times would be sufficient to effectively scavenge various nerve agents, which is why scientists have been looking into mutations that would increase its catalytic activity (142, 208, 209). PON1 can be isolated from plasma but is complexed with HDL cholesterol, which renders isolation and purification expensive and complicated, and the isolated enzyme unstable (142, 209). Directed evolution of a chimeric PON1 via gene shuffling, combined with high-throughput screening, has resulted in PON1 that can quickly hydrolyse the most toxic enantiomers of the G-agents and effectively protect against cyclosarin toxicity in vivo (208, 215). However, no PON1 mutant has been found so far that can quickly hydrolyse V-agents.

Bacterial phosphotriesterases (PT E ) , diisopropylfluorophosphatase (DFPase) isolated from the squid, bacterial prolidase, fungal laccase, and haem chloroperoxidase also hydrolyse OPs (144, 216). These enzymes are used for destroying nerve agent supplies, decontamination of soil, clothing, and water. Encapsulation with nanoparticles gives them potential to counteract NAs (216). The most potent is the PTE obtained from Brevundimonas (Pseudomonas) diminuta. Its enantioselectivity has been redesigned by direct evolution, and the evolved mutants successfully and quickly hydrolyse the most toxic isomers of the V- and G-series and are effective in pre- and post-exposure treatments (217, 218).

There were attempts to transform BChE into a catalytic scavenger by introducing mutations. The first studied variant was that of human BChE with glycine at position 117 replaced by histidine (G117H), which introduced a second nucleophile. This BChE variant can slowly hydrolyse paraoxon, sarin, VX, and some other OPs (189, 216). Other mutants were also tested but were even less efficient than G117H.

Research also looked into biological systems such as monoclonal catalytic antibodies or artificial enzyme systems based on functionalised cyclodextrins with nucleophile groups (219, 220). Yet the greatest potential lies in nano-encapsulated cocktails of enzymes that could be used in injectable formulations and have broad-spectrum activity (144, 216).